Data Collective IV GP LLC's Q2 2022 13F: no position changes

Form 13F-HR for the quarter ended Jun 30, 2022 · filed Nov 14, 2022 · 5 reported positions · accession 0001104659-22-118010

What changed this quarter

No equity positions were opened, closed, increased or reduced in this filing.

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

No changes in the top 10 this quarter

# Security Weight before Weight now
1 Recursion Pharmaceuticals, Inc. (RXRX) 9.0% 39.9%
2 Embark Trucks, Inc. (EMBK) 79.7% 26.6%
3 Evolv Technologies (EVLV) 6.0% 23.3%
4 Rocket Lab USA, Inc. (RKLB) 5.0% 9.2%
5 Mind Medicine (MindMed) Inc. (MNMD) 0.4% 1.0%

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).